Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA. This story matters for Finance & Markets readers tracking broker. Reported by cnbc.com. Read the full original at the source link below.
Originally reported by cnbc.com. BrokerNews.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily broker signal